IMMUNOONCOLOGY360 FEBRUARY 23 -26, 2021 VIRTUAL - LEAD SPONSOR - THE CONFERENCE FORUM
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
IMMUNO - ONCOLOGY 360° 2021
ImmunoOncology360°
February 23 -26, 2021 • Virtual
Lead Sponsor
Executive Sponsors
1 Produced by www.io360summit.com
www.io360summit.com #IO3602021
IMMUNO - ONCOLOGY 360° 2021
CHANGE THE LARGEST, ONCOLOGY
FOCUSED iCRO.
YOUR IMAGE MAXIMIZE DATA AND ENSURE
OPTIMAL IMAGING.
OF WHAT’S
We leverage our imaging expertise to evaluate
every measure of efficacy in early Phase
trials, and ensure optimal clarifications and/or
POSSIBLE
modifications of criterion in registration trials.
GLOBAL TRIALS WITH REAL-TIME
READS AND MULTIPLE CRITERIA.
We perform real-time reads for early stage
to global Phase III Trials. We also deploy
multiple criteria on each image to maximize
NO ONE BETTER COMBINES IMAGING data on efficacy.
TECHNOLOGY, EXPERTISE AND
COMBINE IMAGING EXPERTISE
EXQUISITE SERVICES FROM PHASE I
WITH LEADERSHIP IN COMPLIANCE
THROUGH PHASE III AND IV THAN
AND REGULATORY APPROVAL.
IMAGING ENDPOINTS.
Our expertise and industry leading quality
Imaging Endpoints (IE) is an imaging
management system (iQMS) help ensure all
research and core laboratory that
systems, procedures and data are fully compliant
provides comprehensive imaging CRO
to meet or exceed applicable regulations.
(iCRO) services and technology solutions
throughout the clinical trial process. IE
REVOLUTIONIZING CLINICAL
is the largest oncology focused iCRO
globally, and is widely recognized for TRIALS WHERE REVOLUTION
successfully conducting the industry’s IS NEEDED.
most complex imaging trials. IE’s iCRO
RAPID DETECTION AND
experience spans hundreds of successful
QUANTIFICATION OF RESPONSE.
trials across all phases of development,
including some of the most high-profile, We leverage the most advanced imaging
global registration trials in the industry. technologies and customized criterion to
rapidly detect, predict and quantify response.
RADIOMICS + AI = DEEP IMAGING.
We are a global leader in radiomics, utilizing
proprietary imaging technologies such as
TO LEARN MORE VISIT quantitative textural analysis, Al and other
IMAGINGENDPOINTS.COM advanced tools to develop imaging biomarkers.
We offer comprehensive
global imaging services
from protocol development
to study start-up, conduct,
Scottsdale, AZ / Waltham, MA / Offices Globally
closeout and reporting. 480.314.3070 / imagingendpoints.com
2 www.io360summit.com
IMMUNO - ONCOLOGY 360° 2021 WELCOME
WELCOME WHAT TO EXPECT SUMMARY
Welcome to the 7th annual Immuno-oncology
(IO) 360° virtual summit, a comprehensive program Day One - February 23rd
that convenes stakeholders spanning the science Day One kicks off with Cell and Gene Therapy Day,
and business communities to report on data-driven reporting on the latest cell & gene therapy progress
advancements in immuno-oncology to fight a wider range with a focus on solid tumors. Allogene’s Executive
of cancers. Chairman and Co-founder, Dr Arie Belldegrun
joins life science CEO leader Fred Hassan in a
We are excited to present the program virtually for the first fireside keynote on science, culture, vision and the
time with a top-rated platform and a global reach, and of future of treating cancer for patients. Biotech CEO
course providing the same engaging, thought-provoking leadership joins us to provide their perspectives on
experience you’ve come to expect from us. the business and science of cell and gene therapy. Dr
IO360 ̊ is developed with the input and guidance from Kole Roybal, UCSF delivers a keynote on synthetic
our lead advisors, Dr Axel Hoos, GSK, Dr James Gulley, biology and synthetic circuits and how they can be
NCI, Dr Andrew Baum, Citi, Dr Priti Hedge, Foundation implemented to advance the field. FDA’s Dr Peter
Medicine, Dr Daniel Chen, IGM Biosciences, Dr Raluca Marks joins the program to provide an update on the
Verona, Janssen and Jacqueline Karmel, Roche along with FDA’s efforts to facilitate the development of cell
additional program advisors to whom we offer our sincere and gene therapies for cancer. The day will also take
thanks. a deeper dive into the industry-wide challenges and
opportunities, addressing operational and regulatory
The program includes sessions dedicated to: complexities for cell therapy, and BioPharma cell and
• Discovery / Preclinical Science gene therapy strategies.
• Translational Science & Biomarkers
• Clinical Data Developments Concluding the day is a Cell and Gene Therapy
• Cell and Gene Therapy Debate on Allogeneic versus Autologous with
• Next Generation Bispecifics Allogene’s Rafael Amado and BMS’ Kristen Hege.
• Neoadjuvant/Adjuvant Data
• Cancer Vaccines Day Two - February 24th
• Clinical Operations
• Imaging Aspects Day two opens with a keynote by MD Anderson’s Dr
• Business Developments Padmanee Sharma who addresses: Investigating
• Emerging Technologies Mechanisms of Response and Resistance to
Immune Checkpoint Therapy.
The event delivers a clear set of objectives to foster
scientific exchange over the course of four days. Day one also features plenary sessions focusing on
Discovery and Preclinical Science, Advancements in
During the networking breaks, the exhibiting companies IO Imaging, Clinical Operations and Translational
are available to consult with attendees on a variety of Science and Emerging Biomarkers Part 1.
problem-solving solutions. Attendees also have the
opportunity to arrange one-on-one partnering meetings
The day concludes with a sci-fi type session on Visions
that can be scheduled via Meeting Mojo.
of the Future for Cancer Immunotherapy: Year
Please see page 6 for more information on the partnering 2040 with Allogene’s Dr David Chang and IGM
tool. We would like to thank the entire speaking faculty, Biosciences Dr Daniel Chen followed by a biotech
the sponsors and the supporting partners, for helping roundtable discussion led by Dr Priti Hedge, Foundation
create a program that enhances scientific exchange and Medicine on developing combination strategies.
collaboration for the IO community.
Day Three - February 25th
Sincerely,
Day three opens with a keynote by Dr Elizabeth
Jaffee, Johns Hopkins University who will be
Kate Woda Valerie Bowling discussing Priming the Immune System to Provoke
Conference Director Executive Director Checkpoints: The Path to Maintaining the
Immunotherapy Momentum.
Meredith Sands Bre Bugbee
Executive Director, Marketing Manager Following Dr Jaffee, we are joined by Dr Naiyer Rizvi,
Business Development Columbia University, who will be delivering a Zeitgeist
talk on Evaluating PD1 Benefit After PD1 Failure.
Adam Kolanko Elizabeth Bard
Sales & Business Business Development Additional keynotes include: Dr Lisa Butterfield,
Development Manager Manager
Parker Institute for Cancer Immunotherapy
who addresses Cancer Vaccination and Lessons
Meg Gould Efrosini Zambas
Conference Meeting Learned; Expert Analyst, Dr Andrew Baum, Citi, who
Senior Conference
Planner Planner provides an annual keynote on What’s Next on the IO
Radar? Top 10 Recommendations.
3 www.io360summit.com
IMMUNO - ONCOLOGY 360° 2021 WELCOME / HOPIN INFORMATION
About the Hopin Platform
Day three also features sessions on Neoadjuvant/
Adjuvant data, Cancer Vaccines, Translational You will be using the Hopin platform to take part in the
Science and Emerging Biomarkers Part II and
Business Aspects. The day concludes with a
IO360° virtual conference.
roundtable discussion on Single Cell and Spatial Analysis
led by Merck and 10x Genomics. There are four icons on the left sidebar, each with a
different function.
Day Four - February 26th
Day four opens with a fireside chat with cancer survivor
Oriana Sousa, who shares her experience with Home takes you to the main conference
immunotherapy as an experimental therapy that saved page where you will find the program
her life. Following the fireside chat, Dr Axel Hoos, GSK agenda
delivers a Zeitgeist talk on CTLA-4: 10 Years Later.
We are joined by Dr Roy Baynes, Merck and Dr Plenary is where you will view all the main
Andrew Baum, Citi who will participate in a Cancer stage, non-concurrent sessions
Immunotherapy Debate on the topic of TIGIT: Is this
the Next Big IO Checkpoint Target? Breakout sessions is where you will view
concurrent sessions on different tracks
Day four also features sessions on Next Generation
Bispecifics and Clinical Developments with
presenting companies including Regeneron, Janssen, Visit all of our sponsors to learn more about
IGM Biosciences, Immunocore, Memorial Sloan Kettering how their technologies and solutions that
Cancer Center, Amgen, GSK, Icahn School of Medicine help stakeholders in the IO field.
at Mt Sinai and Genentech.
On the right sidebar you’ll find Q&A,
polling, and messaging.
Speaker Slides
Registered attendees will receive a link within a business
Q&A for plenary stage, breakout sessions
week after the conference to get access to approved and entire event can be accessed here.
speaker slides, which will be hosted on the IO360°
Summit website. Polling from the conference organizers will
Download Instructions be displayed in real time.
www.io360summit.com Private messaging can be done in the
attendee tab.
PRESENTATIONS
Why Visit the Meet the Sponsors Section?
• Find solutions to meet your needs to work with
Enter the following password: and for patients
IMMUNOONCOLOGY3602021! • Register your interest and let a company know
you want to hear more
• Find Resources for surveys and customer service
• Read the latest IO360° Newsletters
On Demand Access Post-Conference
Registered Attendees may use the password below and
will receive the protected link two weeks after the event.
You will have 3 months to view IO360° upon demand. We Value your Feedback
• Visit the Meet the Sponsors tab and go to the
Enter the following password: Customer Service/FAQ booth
IMMUNOONCOLOGY3602021! • You will be emailed an evaluation once the
conference concludes
4 www.io360summit.com
IMMUNO - ONCOLOGY 360° 2021 PARTNERING
Virtual Partnering Meeting Information & Instructions • Once you are logged in, click ‘Search’ to
browse company, company type and delegate
*All times are listed in Eastern Standard Time
listings.
The official virtual networking platform for IO360° is • Click ‘Book Meeting’ and a message will be
Meeting Mojo, a partnering meeting scheduler. This sent to your meeting target asking them to
virtual experience can be done via your desktop or respond to your request. Once the meeting
mobile device, making it easy to continue to interact is confirmed, it will be added to a mutually
in real-time as you stay on top of your meeting available meeting time on your calendars.
requests. Meetings begin the afternoon of Tuesday, Please make sure your calendar is up to date
February 23 and are available through the evening with your schedule.
of Tuesday, March 3. See below for the exact • You can also set your availability for meetings:
partnering times. (specific times can be found under click ‘Schedule’ at the top of the page, then
“scheduling meetings”). click the toggle icon on any available meeting
time for which you do not wish to accept
Benefits of Meeting Mojo meeting requests.
• To respond, click ‘Respond’ in the yellow
• 1:1 Partnering is now virtual! meeting advisory bar below each sender’s
• Meetings times occur for 5 days total profile. Any messages sent to you in connection
• Search other attendee profiles by company type with a meeting are listed in the response panel.
• Schedule 30 minute meetings with potential or • Click ‘Confirm’ or ‘Decline’ to respond, and
existing partners you can also include a short message with your
• Send private message to other attendees response if you wish.
• Create and manage a customized, personal agenda
• Upload photos and documents For more information and complete
instructions, please visit the website at https://
Logging into Meeting Mojo theconferenceforum.org/conferences/immuno-
oncology-360/partnering-info/
Log into your profile at https://io360-2021.meeting-
mojo.com/ with your email address as your
Partnering times are as follows and all meetings
username.
are 30 minutes. Remember, you may set your
schedule for your timezone and preferences:
Password
Day One February 23rd:
When you registered for the IO360° event, within
First meeting starts at 4:30pm EST
48 hours, Meeting Mojo automatically generated
Last meeting ends at 6:30pm EST
a password for you to access your account.
This password was emailed to you as well as a Day Two February 24th:
welcome email. First meeting starts at 4:30pm EST
Last meeting ends at 6:30pm EST
If you do not have your password, you can
request a new one via the password reset link on Day Three February 25th:
the Meeting Mojo website: https://io360-2021. First meeting starts at 4:30pm EST
meeting-mojo.com/ Last meeting ends at 6:30pm EST
Post Event Partnering Times:
Please check your SPAM folder as it may have
landed there. Post-Conference: March 2nd:
First meeting starts at 8:00am EST
Scheduling Meetings Last meeting ends at 4:00pm EST
Meeting times are assigned according to a calendar Post-Conference: March 3rd:
you set up with your availability, once a meeting is
accepted and confirmed. Please refer to Meeting First meeting starts at 8:00am EST
Mojo for your confirmed meeting time. Meetings are Last meeting ends at 4:00pm EST
virtual via video and in the system are referred to as
“Video Chats #1-100”
5 www.io360summit.com
IMMUNO - ONCOLOGY 360° 2021
Innovating today to bring
tomorrow’s medicines
to patients sooner
Join Angela Qu, MD, PhD, Vice President,
Translational Medicine to learn more about
Translating Biomarkers into Precision
Immuno-Oncology Therapy Development
on Feb 24 at 3:05pm
Access some of the best minds to guide your
clinical development programs – Parexel’s Oncology
Center of Excellence
©2021 Parexel International Corporation. All rights reserved.
6 www.io360summit.com
IMMUNO - ONCOLOGY 360° 2021 AGENDA
DAY ONE - TUESDAY, FEBRUARY 23rd Moderated by:
*All times are listed in Eastern Standard Time Michael Kalos, PhD
Independent Consultant, Next Pillar Consulting
8:30 am Panelists:
IO360°/Cell & Gene Therapy Virtual Jennifer Brogdon, PhD
Platform Opens Executive Director, Head of Cell Therapy Research,
This is an opportunity to explore the platform, Exploratory Immuno-Oncology, Novartis Institutes
reach out to fellow attendees and visit the for BioMedical Research (NIBR)
technology and service companies working
Tamara Laskowski, PhD
specifically in immuno-oncology R&D.
Scientific Project Director – CAR NK Program,
Adoptive Cell Therapy Platform, Dept. of Stem
9:00 am Cell Transplantation and Cellular Therapy, MD
Opening Remarks & Welcome Anderson Cancer Center
Kate Woda Hy Levitsky, MD
Director, IO360°
President, Research and Development, Century
Therapeutics
9:10 am
Jakob Dupont, MD
Analyst Evaluation: Cancer Cell Therapy
Landscape, Trends and Future Outlook EVP, Head of Global Research & Development,
Atara Biotherapeutics
Asthika Goonewardene, MBA
Managing Director, Senior Biotech Analyst, Truist
Securities KEYNOTE
9:35 am 10:50 am
FDA’s Efforts to Facilitate the Visionary Entrepreneur Fireside Chat
Development of Cell and Gene Allogene’s Executive Chairman and Co-founder, Dr
Therapies for Cancer Arie Belldegrun joins life science CEO leader Fred
Hassan in a fireside keynote chat on science, culture,
Peter Marks, MD, PhD vision and the future of treating cancer for patients.
Director, Center for Biologics Evaluation and Arie Belldegrun, MD
Research (CBER), FDA Executive Chairman & Co-founder,
Allogene Therapeutics
10:00 am
Ten Minute Break
Fred Hassan, MBA
10:10 am Director, Healthcare and Consumer,
Warburg Pincus
Deep Dive: Addressing Key Issues Of
Cell/Gene Therapy
This discussion, led by internationally recognized T
cell therapy expert Dr Michael Kalos, will provide a
deep dive into key cell therapy challenges including:
• How to overcome the scientific challenges with
allogenic cell therapy?
• How do we make an impact on solid tumors?
• Where do we go beyond t-cells?
• As the field continues to advance how do we think
about cell therapy combinations?
7 www.io360summit.com
IMMUNO - ONCOLOGY 360° 2021 AGENDA
11:10 am 12:20 pm
Biotech CEO Leadership on the Lunch Break and visit the “Meet the
Business and Science of Cell and Gene Sponsors” page
Therapy
Biotech leaders join us to provide their perspectives KEYNOTE
and insights on the current cell and gene therapy
space and additional opportunities to advance cell 12:45 pm
and gene therapy R&D. How Synthetic Biology & Synthetic Circuits
Moderated by: Can be Implemented into Cell Therapy to
Advance the Field
Fred Hassan, MBA
In this talk, Dr Kole Roybal will discuss how his lab
Director, Healthcare and Consumer, Warburg
Pincus is engineering immune cells (e.g. the T cell) to better
sense diseases such as cancer with high fidelity. He
Panelists: will also discuss how to utilize synthetic biology to
David Chang, MD, PhD, customize and control immune cells such that they
perform specific therapeutic functions within the tumor
President, CEO & Co-founder, Allogene
to enhance efficacy and mitigate the risk of toxicity
Therapeutics of these living drugs. Overall, the objective is to seek
Ken Drazan, MD to engineer control over the sense and response
capabilities of therapeutic cells such that they reliably
Co-founder & CEO, ArsenalBio
sense and treat complex diseases with more specificity
Maria Fardis, PhD and potency than small molecules or biologics.
President and CEO, IOVANCE Biotherapeutics
Vijay Reddy, MD Kole Roybal, PhD
Assistant Professor, Microbiology &
Chief, Research and Development Officer, Tmunity Immunology, University of California, San
Dolores Schendel, PhD Francisco
CEO & CSO, Medigene AG
Pascal Touchon 1:10 pm
President & CEO, Atara Biotherapeutics Five Minute Break
8 www.io360summit.com
IMMUNO - ONCOLOGY 360° 2021 AGENDA
BioPharma Cell/Gene Therapy Strategies
TRACK A TRACK B
1:15 pm 1:15 pm
GSK Parent-Child Cell Therapy Development Preparing the BLA for First TCR T-cell Therapy
Strategy: A Novel Clinical and Regulatory and Planning to Make Cell Therapies Mainstream
Framework to Evaluate a Series of Cell Helen Tayton-Martin, PhD
Therapies in Rapid Sequence
Chief Business Officer, Adaptimmune
In this talk, Dr Aiman Shalabi will summarize GSK’s
parent-child cell therapy development strategy and how
they are executing it.
Aiman Shalabi, PharmD
VP R&D, Cell and Gene Therapies, GSK
1:30 pm 1:30 pm
Engineering Gamma Delta T cells with CARs Enhanced NK Cell Function to Provide
and T Cell Receptors Resistance to TGFβ
Stewart Abbot, PhD James Trager, PhD
Chief Scientific and Operating Officer, Adicet Bio Chief Scientific Officer, Nkarta Therapeutics
1:45 pm 1:45 pm
Building the Takeda Cell Therapy Portfolio Tumor Infiltrating Lymphocyte Cell Therapy for
Through Collaborations Treatment of Solid Tumors
Gary Shapiro, PhD Maria Fardis, PhD
Director, Immunology Research, Takeda President and CEO, IOVANCE Biotherapeutics
Pharmaceuticals
2:00 pm 2:00 pm
Neoantigen directed PBL-based Cell Therapy Next-generation Sequencing clonoSEQ®
can Achieve High Breadth and Purity Against Assay to Assess Minimal Residual Disease
Tumor Specific Targets (MRD) in Patients with Blood Cancers
This talk will provide updates on GEN-011, a Thomas Manley, MD
neoantigen and PBL-based cell therapy product and
VP, Clinical Development and Medical Affairs, Adaptive
focus specifically on:
Biotechnologies
• Neoantigen-specific expansion and how it generates
pure and specific autologous NPTs (neoantigen targeted
peripheral T cells) in the absence of high dose IL-2
• Data showing 96% of the NPTs are neoantigen
specific, successfully targeting 89% of intended
neoantigen targets with up to 30 mutations included
• Ongoing pilot study will evaluate safety and tumor
targeting in patients with solid tumors
Tom Davis, MD
Chief Medical Officer, Genocea
9 www.io360summit.com
IMMUNO - ONCOLOGY 360° 2021 AGENDA
2:15 pm 3:20 pm
Ten Minute Break Operational Execution of Cell/Gene
Therapy Programs: Challenges and
2:25 pm Opportunities
Regulatory Opportunities to Accelerate This discussion will address the operational
the Development of Cell Therapies challenges in the cell and gene therapy space
pertaining to supply chain operations and site
This panel will discuss and describe how current activation. Key areas include:
regulatory and policy discussions (FDA guidance, • Identifying differences between traditional
PDUFA) could be setup to facilitate the science execution of getting these programs delivered?
and innovation of cell therapies. Key topics include: How is it different?
• Opportunities to accelerate entry into the clinic for • What are the new technologies out there helping
exploratory studies us to try and solve this problem? What digital
• Explore lighter cGMP requirements for early platforms are being pushed?
investigational products/phases • What are the issues at the site level that we need
• Identify how to best pivot from that data (if to be aware of?
positive) to a full fledged phase I/II IND (Role of • Each group is trying to implement their own standards,
parent and cousin INDs) and those standards differ across companies.
Moderated by: • The sites are trying to cater to multiple types of
standards. There is no harmonization at the site level.
Mark Stewart, PhD
Vice President, Science Policy, Friends of Cancer Moderator:
Research Rachel Gaskell
Panelists: Senior Director, Clinical Development, GSK
Panelists:
Lisa Butterfield, PhD
VP, Research and Development, Parker Institute Shree Patel, PhD
for Cancer Immunotherapy SVP, Clinical Operations, Achilles Therapeutics
Julie K Jadlowsky, PhD Deborah Phippard, PhD
Director, Translational Science, Center for Cellular Global Head, Research, Precision for Medicine
Immunotherapies, Perelman School of Medicine,
Scott Welden
University of Pennsylvania
Senior Project Manager, Novel and Emerging
Chris Ramsborg, PhD Therapies, Oncology and Hematology Business
Vice President, Cell and Gene Therapy Process Unit, Syneos Health
Science & Technology, BMS
Aiman Shalabi, PharmD Cell/Gene Therapy Debate
VP R&D, Cell and Gene Therapies, GSK 4:00 pm
Autologous vs Allogeneic
3:05 pm Rafael Amado, MD
Considerations Towards Successful IND EVP, Research and Development & CMO, Allogene
Submissions of Cell and Gene Therapy Therapeutics
Hardeep Samra, PhD Kristen Hege, MD
Principal Consultant, Regulatory, Halloran SVP, Early Clinical Development, Hematology/
Consulting Group Oncology & Cell Therapy, BMS
Niki Gallo Moderated by:
Associate Principal Consultant, Regulatory Affairs, Aiman Shalabi, PharmD
Halloran Consulting Group VP R&D, Cell and Gene Therapies, GSK
4:30 pm
End of day one. Partnering meetings begin
on the Meeting Mojo platform.
10 www.io360summit.comIMMUNO - ONCOLOGY 360° 2021 AGENDA
Discovery and Preclinical Plenary
DAY TWO - WEDNESDAY, FEBRUARY 24th
Session
*All times are listed in Eastern Standard Time
10:30 am
9:15 am Role of CD4 in Response to PD1
IO360° Virtual Platform Opens Blockade in Heme Malignancies
This is an opportunity to explore the platform, Margaret Shipp, MD
reach out to fellow attendees and visit the Douglas S. Miller Chair, Chief, Division of
technology and service companies working Hematologic Neoplasia, Department of Medical
specifically in immuno-oncology R&D. Oncology, Dana-Farber Cancer Institute
10:45 am
9:50 am Targeting TGF Beta in Immuno-
Opening Remarks & Welcome Oncology: Mechanisms, Challenges
and Opportunities
Kate Woda
Director, IO360° Shannon Turley, PhD
Executive Director, Cancer Immunotherapy,
OPENING KEYNOTE Genentech
10:00 am 11:00 am
Opening Keynote: From the Clinic to Targeting the ICOS Pathway with
the Lab: Investigating Mechanisms of Feladilimab, a Differentiated Agonist
Response and Resistance to Immune Antibody for Cancer Immunotherapy
Checkpoint Therapy
Sapna Yadavilli
In this keynote, MD Anderson’s Dr Padmanee
Clinical Biomarker Director, Experimental Medicine
Sharma, will discuss her work around investigating
Unit, Oncology, GSK
and exploring targets to improve the anti-tumor
responses with immune checkpoint therapy
in “cold” tumors such as prostate cancer and 11:15 am
glioblastoma and other cancers that have not Ten Minute Break
responded well to immune checkpoint therapy.
11:25 am
Padmanee Sharma, MD, PhD
Next Generation Immune Checkpoints:
Professor of Genitourinary Medical
Oncology and Immunology in the Division of Deciphering Key Roles in the TME
Cancer Medicine, MD Anderson Cancer
Center Catherine Sabatos-Peyton, PhD
Executive Director, Head of Immune Modulation,
Novartis Institutes for BioMedical Research
11:40 am
Preclinical and Translational updates
on SEA-TGT, an anti-TIGIT Antibody for
Multiple Tumor Types
This talk will include robust preclinical mechanisms of
action for Seagen’s sugar engineers antibody, SEA-TGT,
an anti-TIGIT antibody, along with early clinical findings,
phase 1 design and preliminary biomarker data.
Haley Neff-LaFord, PhD, DABT
Director, Toxicology and Translational Sciences
Team Lead, Seagen
11 www.io360summit.comIMMUNO - ONCOLOGY 360° 2021 AGENDA
11:55 pm 12:10 pm
FT536 – An iPSC-derived, Multiplexed Quick Fire Presentations on Solutions
Engineered CAR MICA/B NK Cell that Support Immuno-Oncology R&D
Product Targeting Solid Tumors
Sarah Kolitz, PhD, DABT, VP
• Induced pluripotent stem cells (iPSCs) serve as a
unique starting cell source for off-the-shelf cancer Translational MedicineTeam Lead, Immuneering
immunotherapy
John Pagliuca
• Through single cell engineering, the derived iPSC
MCB is renewably manufactured to generate Chief Growth Officer, HealthMyne
homogenous, cost effective and available on-
demand engineered CAR-T and CAR-NK cells Sharla White, PhD
• CAR-MICA/B is a novel pan-tumor targeting Director, Research & Development, ClearLight
strategy Biotechnologies, Inc
• FT536 is an off-the-shelf NK cell uniformly
consisting of four anti-tumor modalities that
uniquely synergize with other therapeutic
approaches such as mAbs and radiation therapy 12:25 pm
for an effective elimination of various solid tumors Lunch Break and visit the “Meet the
Bahrem (Bob) Valamehr, PhD Sponsors” page
Chief Development Officer, Fate Therapeutics
Breakout Choices: Advancement In IO Imaging and Clinical Operations
TRACK A: Advancements in IO Imaging TRACK B: Clinical Operations
1:00 pm 1:00 pm
Reponse Criteria for Intratumoral Biomarker Focused IO Clinical Trial Design
Immunotherapy in Solid Tumors: itRECIST This talk will address how biomarker considerations can influence trial
design. Key topics include:
Gregory Goldmacher, MD, PhD
• Thinking critically about the key biomarker questions you hope to
Executive Director, Translational Biomarkers & Head, answer in the trial (eg: confirmatory or exploratory)
Clinical Imaging, Merck Research Laboratories • Identifying some of the common trial designs to consider based on
your biomarker strategy (selection vs enrichment vs stratification)
• Common pitfalls of including biomarkers into clinical trial design
Chris Cabanski, PhD
Director, Biostatistics, Parker Institute for Cancer
Immunotherapy
1:15 pm 1:15 pm
Applying a Novel AI Approach to Concluded Applying Predictive Machine-Learning to
Clinical Trial Data to Predict Response to Improve Enrollment in Biomarker-Driven Clinical
Cancer Immunotherapy Trials
Anant Madabhushi, PhD Joel Greshock
Donnell Institute Professor, Director, Ctr for Computational
Imaging & Personalized Diagnostics, Departments of Biomedical Vice President, Oncology Data Sciences, Janssen
Engineering, Urology, Radiology, Pathology, Radiation Oncology,
Electrical Eng & Comp Science and Gen Med Sciences, Case
Western Reserve University
12 www.io360summit.comIMMUNO - ONCOLOGY 360° 2021 AGENDA
Breakout Choices: Advancement In IO Imaging and Clinical Operations
TRACK A: Advancements in IO Imaging TRACK B: Clinical Operations
1:30 pm 1:30 pm Addressing Operational Challenges Impeding
Novel Methods for Imaging the Immune System Patient Access to Trials: Next Steps
As new therapies for enhancing the immune response to tumor antigens Jacob Aptekar, MD, PhD
become available, having the ability to track the changes of the immune
system in a non-invasive manner becomes ever more important. This Senior Director, Product Management (Integrated Evidence),
short presentation will focus on our current and upcoming radiologic Acorn AI, a Medidata company
imaging strategies used to evaluate the dynamic changes in the immune
system that can be implemented in clinical trials.
Ron Korn, MD, PhD
Founder & CMO, Imaging Endpoints
1:45 pm 1:45 pm Operational Continuity: Dealing with
Radiomics and AI for Predicting Tumor Response Disruptions of a Pandemic
in Immuno-Oncology
This panel focuses on operational pandemic management for clinical
Charles Ferte, MD, PhD trials and how to deal with the trial disruptions in a situation such as
Senior Director, Global Project Leader (Product Development we have been experiencing.
Team Leader), Oncology R&D, AstraZeneca Moderated by:
2:00 pm Andy Lee
Towards Predictive Analytics of IO Toxicity and SVP, Global Head, Clinical Operations, Merck
Efficacy Outcomes From Real-World Clinical Data
Panelists:
Jan Wolber PhD,
Global Product Leader Digital, Pharmaceutical Diagnostics, Alice Donnelly
GE Healthcare SVP, Hematology and Oncology Therapeutic Unit Head, PPD
2:15 pm Carol Haddad
Interventional Imaging in Immunotherapy: Current
Approaches, Future Directions Executive Director, Oncology Clinical Sciences and Study
• Future of immune imaging in the relation to immune response Management, Merck
and where we are going with it
• How we can use imaging to elicit new paradigms for clinical trials Michele Sample
• Utilizing imaging to understand the kinetics of response; early Vice President, Late Stage Oncology Clinical Operations,
progression through imaging and late response, etc.
• Data on imaging for response using radiolabeled pd1 antibodies, AstraZeneca
immuno PET
• Imaging in the CNS to evaluate response Simon Trowell
• PET Imaging to detect the release of granzymes by activated VP, Clinical Development Quality & Risk Management, GSK
immune cells
• PET Tracers with CD8 cells and how that relates to response Jim Wise
Moderated by: Executive Director & Head of Center for Immuno-oncology,
Omid Hamid, MD Cellular, and Gene Therapy, PRA Health Sciences
Chief, Research and Immunotherapy / Co-Director, Cutaneous
Malignancy Program, The Angeles Clinic and Research
Institute / Cedars-Sinai CANCER
Panelists:
Gregory Goldmacher, MD, PhD
Executive Director, Translational Biomarkers & Head, Clinical
Imaging, Merck Research Laboratories
Ron Korn, MD, PhD
Founder & CMO, Imaging Endpoints
Alexander Menzies, PhD
Medical Oncologist and Associate Professor of Melanoma
Medical Oncology, Imaging Endpoints
Ian Wilson
Chief Executive Officer, ImaginAb, Inc.
13 www.io360summit.comIMMUNO - ONCOLOGY 360° 2021 AGENDA
2:45 pm 3:35 pm
Break High-throughput Identification of
Antigen-specific TCRs for Personalized
Translational Science and Therapeutics
Emerging Biomarkers Plenary Sharon Benzeno, PhD
Session Part 1 Chief Business Development Officer, Adaptive
Biotechnologies
2:50 pm
Behind the Science: Neoadjuvant and 3:50 pm
Adjuvant Immunotherapy A Spatial Biology Approach for the
Development and Clinical Validation
Charles Drake, MD, PhD of Predictive Biomarker Signatures in
VP, Immuno-Oncology, Janssen Immuno-Oncology
3:05 pm Gavin Gordon, PhD
Translating Biomarkers into Vice President, Clinical Market Development, Akoya
Precision Immuno-Oncology Therapy Biosciences Inc
Development
In this talk, Dr Angela Qu, will present and offer IO360° Debate
insights into incorporating the rapidly evolving and
complex biomarkers into precision I/O therapy
development by discussing: 4:00 pm
Visions of the Future for Cancer
• Current and emerging biomarkers in oncology Immunotherapy: Year 2040
that guide I/O treatment and trial decision across
tumor types Cancer immunotherapy experts Dr Dan Chen,
• Challenges associated with the complex and IGM Biosciences and Dr David Chang, Allogene,
multifaceted biomarker “conundrum” in I/O clinical present in a Sci-Fi-style fashion, how they envision
development
• Strategic considerations and approach to cancer immunotherapy working in 10-20 years.
incorporate biomarkers from molecular testing to They will have the opportunity to critique each others
data utility into streamlined I/O trials. approach and will open the dialogue to the audience.
Angela Qu, MD, PhD Attendees will gain a better understanding of:
Vice President, Translational Medicine, Parexel • The challenges that immunotherapy has today
• How technology and science can improve
therapeutics over the next 10 – 20 years
3:20 pm • How different immunotherapies might interact
TCR-engineered T cells Targeting HPV-
16 E7 for Patients with Metastatic HPV- David Chang, MD, PhD
Associated Epithelial Cancers President, CEO & Co-founder, Allogene
• We conducted a first-in-human, phase I clinical Therapeutics
trial testing TCR-engineered T cells targeting HPV- Daniel Chen, MD, PhD
16 E7 in patients with metastatic HPV-associated
epithelial cancers. Objective clinical responses Chief Medical Officer, IGM Biosciences
were seen in 6 of 12 patients including 4 of 8
patients with anti-PD-1 refractory disease. Moderated by:
• Translational research studies indicate that
clinical activity may be limited by tumor-intrinsic Charles Graeber
genetic defects in molecules important for antigen Award-winning Journalist and Author of The
presentation and interferon response. Breakthrough:Immunotherapy and the Race to
• Strategies being explored to improve clinical Cure Cancer
outcomes include the use of membrane-tethered
cytokines and treatment at earlier stages of disease.
Scott Norberg, DO
Assistant Research Physician, Genitourinary
Malignancies Branch, National Cancer Institute (NCI)
14 www.io360summit.comIMMUNO - ONCOLOGY 360° 2021 AGENDA
DAY THREE - THURSDAY, FEBRUARY 25th
4:30 pm *All times are listed in Eastern Standard Time
Partnering Meetings begin on Meeting 8:45 am
Mojo
IO360° Virtual Platform Opens
This is an opportunity to explore the platform, reach
4:40 pm out to fellow attendees and visit the technology and
Zoom Small Group Interactive Discussion service companies working specifically in immuno-
oncology R&D.
The concluding afternoon of day two features a
30 minute small group discussion. This interactive
discussion is first come first serve and has limited
9:20 am
capacity. Registration is required in advance. Opening Remarks & Welcome
Kate Woda
To register for the discussion please email service@
Director, IO360°
tcfllc.org with the Subject Line: IO360° Group
Discussion Reservation February 24th.
OPENING KEYNOTE
9:30 am
Priming the Immune System to Provoke
Biotech Roundtable on Developing Checkpoints: The Path to Maintaining
Combination Strategies the Immunotherapy Momentum
This roundtable, designed for small and emerging Dr Elizabeth M Jaffee, Johns Hopkins University, will
biotechs, will answer questions from experts on present data from studies of vaccine plus immune
how to develop combination strategies. checkpoint combination therapy demonstrating the
ability to activate anticancer immune responses in
• How do you design combination clinical trials patients with classically immune resistant cancers. Data
• How do you to this when your combining partner will include single cell transcriptomics and proteomics
has mono therapy activity which are uncovering mechanisms of synergy.
• What would it take for small biotechs to get set up
for combination strategies Elizabeth Marion Jaffee, PhD
Led by: Deputy Director, The Sidney Kimmel
Comprehensive Cancer Center, Johns
Priti Hegde, PhD Hopkins University
Chief Scientific Officer, Foundation Medicine
ZEITGEIST TALK
Edith Perez, MD
9:55 am
Chief Medical Officer, Bolt Biotherapeutics Evaluating PD1 Benefit After PD1
Failure
• In this talk, Dr Naiyer Rizvi, Columbia University,
sheds light on the benefit of giving PD1 to PD1
patients specifically addressing:
• What do we know about any setting, lung cancer
and otherwise, where PD1 has been given after PD1
and a conclusion can be drawn, what effect that
has? What does PD1 alone do after PD1 failure?
• What do we know about response rate, PFS and
survival in terms of clinical outcomes after PD1?
• What do we know about combinations of PD1 after
PD1?
Naiyer Rizvi, MD
Price Family Professor of Medicine;
Director, Thoracic Oncology; Co-Director,
Cancer Immunotherapy, Columbia
University Irving Medical Center
15 www.io360summit.comIMMUNO - ONCOLOGY 360° 2021 AGENDA
10:20 am
Ten Minute Break
Breakout Choices: Neoadjuvant & Adjuvant Data and Cancer Vaccines
TRACK A: Neoadjuvant & Adjuvant Data TRACK B: Cancer Vaccines
10:30 am 10:30 am
Updates on Bladder Cancer in the Neoadjuvant Development of Neoantigen Specific Vaccines
Setting Karin Jooss, PhD
Andrea Necchi, MD Chief Scientific Officer, Gritstone Oncology
Associate Professor / Director of Genitourinary Medical
Oncology, Vita-Salute San Raffaele University / IRCCS
San Raffaele Hospital
10:45 am 10:45 am
Updates on Bladder Cancer in the Adjuvant Next Generation Synthetic Vaccines
Setting
Anish Suri, PhD
Andrea Apolo, MD President & Chief Scientific Officer, Cue Biopharma
Head, Bladder Cancer Section, National Cancer
Institute
11:00 am 11:00 am
Updates on Lung Cancer in the Adjuvant and A Multifaceted Approach to ImmunoTherapy
Neoadjuvant Setting Including a Therapeutic Vaccine
Joshua E Reuss, MD Jeffrey Schlom, PhD
Assistant Professor of Medicine, Georgetown Lombardi Chief, Laboratory of Tumor Immunology and Biology,
Comprehensive Cancer Center Center for Cancer Research, National Cancer Institute
11:15 am 11:15 am
Triple Negative Breast Cancer in the Cancer Vaccines and T Cell Therapy
Neoadjuvant Setting Nora Disis, MD
Elizabeth A Mittendorf, MD, PhD Helen B Slonaker Endowed Professorship for Cancer
Robert and Karen Hale Distinguished Chair in Surgical Research; Professor, Department of Medicine, Division
Oncology, Director of the Breast Immuno-Oncology of Oncology; Director, Tumor Vaccine Medical Oncology,
Program, Brigham and Women’s Hospital, Dana- University of Washington Medicine
Farber Cancer Institute
16 www.io360summit.comIMMUNO - ONCOLOGY 360° 2021 AGENDA
TRACK A: Neoadjuvant & Adjuvant Data TRACK B: Cancer Vaccines
11:30 am 11:30 am
Neoadjuvant/Adjuvant Expert Discussion Vaccine Expert Discussion
Expert speakers from the neoadjuvant/adjuvant Expert speakers from the Vaccine session come
session come together to address emerging trends, together to address emerging trends, future outlooks
future outlooks and take audience Q&A. and take audience Q&A.
Led By: Led By:
Alexandra Snyder, MD Sharon Benzeno, PhD
Associate Vice President / Head, Translational Chief Business Development Officer, Adaptive
Oncology / Executive Director, Oncology Early Biotechnologies
Development, Merck Research Labs Discussants:
Discussants: Karin Jooss, PhD
Andrea Apolo, MD Chief Scientific Officer, Gritstone Oncology
Head, Bladder Cancer Section, National Cancer Jeffrey Schlom, PhD
Institute Chief, Laboratory of Tumor Immunology and Biology,
Andrea Necchi, MD Center for Cancer Research, National Cancer Institute
Associate Professor / Director of Genitourinary
Anish Suri, PhD
Medical Oncology, Vita-Salute San Raffaele
President & Chief Scientific Officer, Cue Biopharma
University / IRCCS San Raffaele Hospital
Nora Disis, MD
Elizabeth A Mittendorf, MD, PhD Helen B Slonaker Endowed Professorship for Cancer
Robert and Karen Hale Distinguished Chair in Surgical Research; Professor, Department of Medicine,
Oncology, Director of the Breast Immuno-Oncology Division of Oncology; Director, Tumor Vaccine Medical
Program, Brigham and Women’s Hospital, Dana- Oncology, University of Washington Medicine
Farber Cancer Institute
Joshua E Reuss, MD
Assistant Professor of Medicine, Georgetown
Lombardi Comprehensive Cancer Center
12:00 pm
Lunch Break and visit the “Meet the Sponsors” page
AFTERNOON KEYNOTE
12:30 pm
Cancer Vaccination: Lessons Learned
Dr Lisa Butterfield, Parker Institute for Cancer Immunotherapy will present recent studies on key aspects of
cancer vaccine biology that impact in vivo immunity and clinical outcome in patients, as well as future directions
for where cancer vaccines may fit into the immunotherapy armamentarium.
Lisa Butterfield, PhD
VP, Research and Development, Parker Institute for Cancer Immunotherapy
17 www.io360summit.comIMMUNO - ONCOLOGY 360° 2021 AGENDA
Business Aspects Plenary 1:45 pm
New Dynamics of BD and Covid and the
Session Impact on IO - Lessons Learned
ANALYST KEYNOTE John Cantello, PhD
12:55 pm VP, Business Development, Oncology Therapy Area,
GSK
Analyst Keynote: What’s Next on the IO
Radar? Top 10 Recommendations from 2:05 pm
Citi’s Expert Analyst, Dr Andrew Baum Dealmaking & Collaborations in the
In this talk, Dr Andrew Baum will provide an Time of COVID19
evaluation of the IO landscape and advancements This panel will address the current nature of deals
from 2020 and include his annual top 10 target and collaborations during a pandemic where
recommendations. business developments have been conducted in a
remote manner. Key topics:
• How have deals and collaborations approach
Andrew Baum, MD changed as a result of COVID19 and how has the
Managing Director, Equity Research, Citi industry adapted?
• BioPharma perspective on remote business
developments and the impact?
• As a result, has there been a change in series
1:15 pm funding/ IPOs?
Panel: Role of China in the BD Process Moderated by:
This panel will bring together chinese biotechs
to share how they are partnering with additional Jeffrey Bockman, PhD
IO companies to advance cancer treatments for EVP, Oncology Practice Head, Cello Health
patients. This will include partnering strategies and BioConsulting (Previously Defined Health)
decision making. Panelists:
Moderated by:
Madee Gooriah, PharmD
Andrew Baum, MD
Senior Director, Oncology Search & Evaluation,
Managing Director, Equity Research, Citi BMS
Panelists:
Mark Simon, MBA
Meeta Chatterjee, PhD
Co-founder & Advisor, Torreya Partners
SVP, Global Business Development, Legend
Biotech Helen Tayton-Martin, PhD
Angus Grant, PhD Chief Business Officer, Adaptimmune
SVP, Chief Business Executive, BeiGene Mai-Britt Zocca, PhD
Weimin Tang CEO and Founder, IO Biotech
EVP, Global Business Head, I-Mab Biopharma
2:35 pm
10 Minute Break
18 www.io360summit.comIMMUNO - ONCOLOGY 360° 2021 AGENDA
Translational Science and Emerging Moderated by:
Biomarkers Plenary Session Part 2 Theresa LaVallee, PhD
VP, Translational Medicine and Regulatory Affairs,
2:45 pm Parker Institute for Cancer Immunotherapy
Biomarkers in IO: Challenges and Jared Lunceford, PhD
Putative Benefits of Multi-omics Distinguished Scientist, Biostatistics and
Technologies Research Decision Sciences, Merck Research
• Evaluating single cell omics to understand the Laboratories
heterogeneity in immune and tumor cells Angel A Rodriguez, MD
• Multi-omic biomarkers for patient selection in solid Oncology Medical Director, Natera
tumor IO: is there a path to more personalized
therapy? Samik Upadhaya, PhD
• In an era of ‘targeted’ therapies against cell-intrinsic Research Analyst, Anna-Maria Kellen Clinical
mechanisms (e.g. PARP, NTRK, BRAF) and surface Accelerator and Venture Fund, Cancer Research
molecules (Nectin-4, HER2), is there a path forward Institute (CRI)
for pan-tumor biomarkers, or is multi-tumor more
likely to be the dominant development mechanism? 3:25 pm
Five Minute Break
Translational Science and Emerging Biomarkers Track Choices
TRACK A TRACK B
3:30 pm 3:30 pm
Translational Learnings for Cellular Therapies Industry Perspective on Neoadjuvant and
Inform Next-Generation Strategies Adjuvant Designs, Challenges and Opportunities
Teresa (Teri) Foy, PhD Nageatte Ibrahim, MD
Senior Vice President, Research and Early Development Associate Vice President, Global Oncology Clinical
Immuno-Oncology and Cell Therapy, BMS Development, Merck
3:45 pm 3:45 pm
AI Coupled with Mass Spectrometry for Pathology in the 21st Century: Multiplex
Immunotherapy Diagnostic Test Development Analysis of the Immune Microenvironment in
Tissue Biopsies
Robert Georgantas III, PhD
SVP, Research and Translational Science, Biodesix Keith Wharton, MD, PhD
Vice President, Medical Director, Ultivue
4:00 pm 4:00 pm
Accelerating Drug Development in Early Stage ctDNA for Potential Application to Clinical Trial
Solid Tumors: Novel Digital and Molecular Designs
Endpoints for Neoadjuvant/Adjuvant Disease
Darren Hodgson
David Shames, PhD Global Project Leader & Executive Translational Medicine
Senior Director, Cancer Immunotherapy Biomarkers & Staff Strategy, AstraZeneca
Scientist in Oncology Biomarker Development, Genentech
19 www.io360summit.comIMMUNO - ONCOLOGY 360° 2021 AGENDA
TRACK A TRACK B
4:15 pm 4:15 pm
Integration of Single Cell Multi-omics and Machine Single Cell and Spatial Analysis:
Learning to Unlock Immunological Insights for Mechanisms of Response and Resistance to
Improving Diagnostics and Therapeutics Immunotherapy
• Unravel the complex interplay among the immune, tumor
Ansuman Satpathy, MD, PhD and stromal compartments in the tumor microenvironment
Assistant Professor, Department of Pathology / Scientific with single cell and spatial analysis
Founder, Stanford University School of Medicine / • Track the anti-tumor immune response through single cell
Immunai profiling of T and B cell clonal lineages and phenotypes
• Uncover the epigenetic regulators of immune cell
phenotypes governing response and resistance to
immunotherapies
• Explore published case studies of how multiomic single
cell and spatial analysis were applied to advance our
understanding of mechanisms driving response and
resistance to immunotherapy.
Bruce Adams, PhD
Staff Scientist, 10X Genomics
4:30 pm
10 Minute Break Partnering Meetings begin on Meeting Mojo
Zoom Small Group Interactive Discussion
4:40 pm – 5:10 pm EST
The concluding afternoon of day three features a 30 minute small group discussion. This interactive discussion is
first come first serve and has limited capacity. Registration is required in advance.
To register for the discussion please email service@tcfllc.org with the Subject Line: IO360° Group Discussion
Reservation February 25th.
Single Cell and Spatial Analysis
Spatial transcription ICD tells you where in the TME each cell of interest (eg Cd8 T cell, MDSC, etc is) and what
that cell is expressing at that moment in time. This roundtable will discuss:
• How many and discordant analyses can be combined and what are the limitations there
• How can we best leverage the information to understand the function and history of each cell
• How can we connect that information to an understanding of what in the TME is influencing the cell’s function,
and what influence that cell has on the TME
Led by:
Bruce Adams, PhD
Staff Scientist, 10X Genomics
Dan Chang, PhD
Principal Scientist, Single cell sequencing lead, Merck Research Laboratories
20 www.io360summit.comIMMUNO - ONCOLOGY 360° 2021 AGENDA
DAY FOUR - FRIDAY, FEBRUARY 26th
*All times are listed in Eastern Standard Time Moderated by:
8:45 am Axel Hoos, MD, PhD
IO360° Virtual Platform Opens SVP, Therapeutic Area Head, Oncology R&D, GSK
This is an opportunity to explore the platform, reach Panelists:
out to fellow attendees and visit the technology and Kristen Hege, MD
service companies working specifically in immuno- SVP, Early Clinical Development, Hematology/
oncology R&D. Partnering Meetings will also be Oncology & Cell Therapy, BMS
taking place during this time on Meeting Mojo.
Yvonne Lu
Executive Search and Leadership Consultant,
9:20 am Russell Reynolds Associates
Opening Remarks
Tracy Vanderslice
Kate Woda Vice President and Head, Global Clinical Sciences &
Director, IO360° Delivery, GSK
VIP FIRESIDE CHAT ZEITGEIST TALK
10:30 am
9:30 am CTLA-4: 10 Years Later
VIP Fireside Chat: Oriana Sousa’s
Immunotherapy Journey In this talk, GSK’s Dr Axel Hoos, takes a deep dive
into the CTLA-4 data over the course of the past
We are honored to welcome Oriana Sousa, 10 years, from its approval, and discusses whether
the first hypercalcemic small cell ovarian CTLA-4 offers something special beyond melanoma.
cancer patient in the world to ever receive
immunotherapy, who in this fireside chat
provides personal insights on her experience Axel Hoos, MD, PhD
with Nivolumab as an experimental therapy. SVP, Therapeutic Area Head, Oncology
R&D, GSK
VIP Patient Guest:
Oriana Sousa .
Patient Advocate 11:00 am
Ten Minute Break
Moderated by:
Theresa LaVallee, PhD
VP, Translational Medicine and 11:10 am
Regulatory Affairs, Parker Institute for Modified NK Cells in Combination with
Cancer Immunotherapy anti-CD38 for Multiple Myeloma and
Future Therapeutic Areas
Dmitri Wiederschain, PhD
10:00 am Vice President, Global Head, Immuno-Oncology
Diversity and Inclusion and The Impact Research Therapeutic Area, Sanofi
on IO
This panel will address diversity and inclusion
issues that influence the IO space and ways to
overcome them.
21 www.io360summit.comIMMUNO - ONCOLOGY 360° 2021 AGENDA
Bispecifics Plenary Session IO360° DEBATE
1:10 pm
11:30 am
Cancer Immunotherapy Debate:
Update on Teclistamab, a B-cell TIGIT: Is this the Next Big IO
Maturation Antigen (BCMA) × CD3 Checkpoint Target?
Bispecific Antibody, in Relapsed and/or
Refractory Multiple Myeloma (RRMM) Roy Baynes, MD, PhD
Global Head, Clinical Development, Merck
Raluca Verona, PhD
Research Labs
Senior Director, Head of Immune Oncology
Andrew Baum, MD
Translational Research, Janssen R&D
Managing Director, Equity Research, Citi
Moderated by:
11:45 am
Priti Hegde, PhD
Regeneron’s State of Efforts in
Bispecifics and Emerging CoStim Chief Scientific Officer, Foundation Medicine
Clinical Trial Portfolio
Israel Lowy, MD, PhD
Clinical Developments
SVP, Clinical Sciences, Head, Translational Science
and Oncology, Regeneron Pharmaceuticals Plenary Session
1:40 pm
12:00 pm What’s Next: Mercks Expanding IO
Stimulation, Function and Next Pipeline
Generation Bispecific T cell
Engagement Utilizing an Engineered Roy Baynes, MD, PhD
Multimeric IgM Platform Global Head, Clinical Development, Merck
Research Labs
Daniel Chen, MD, PhD
Chief Medical Officer, IGM Biosciences
1:55 pm
Keynote 177 MSI High Randomized
12:15 pm Data
Tebentafusp: Clinical Validation of a
Luis Diaz, MD
Soluble TCR Bispecific Platform
Head of the Division of Solid Tumor Oncology;
David Berman, MD, PhD Grayer Family Chair, Memorial Sloan Kettering
Head, Research and Development, Immunocore Cancer Center
12:30 pm 2:10 pm
Lunch Break and visit the “Meet the Bispecific T cell engagers (BiTEs ®)
Sponsors” page - Clinical Updates in Solid Tumors &
Hematological Malignancies
Dirk Nagorsen, MD, PhD
Vice President, Early Development TA Head
Oncology, Amgen
22 www.io360summit.comIMMUNO - ONCOLOGY 360° 2021 AGENDA
2:25 pm UPCOMING CONFERENCES
DREAMMing up Advances in MM: PATIENTS AS PARTNERS US
Synergistic Potential of Belantamab The only conference putting the patient voice on the same level
Mafodotin as Combination Therapy as industry and government in finding solutions to engage and
empower patients in the clinical trial process. Join clinical trial
Ira Gupta, MD leaders from Pharma, Patient Advocacy and Government.
APRIL 7-9, 2021
Vice President, Medicines Development Leader –
Oncology, Genentech
CLINICAL RESEARCH AS A CARE OPTION
Bringing together clinical research and healthcare communities
to address the value, opportunities, and challenges to integrate
2:40 pm clinical research as a care option for patients.
CART and Bispecifics: Who’s the Right APRIL 26 - 27, 2021
Candidate?
DRUG DELIVERY WEST
In this talk, Dr Deepu Madduri provides a This event is for biotech, pharma and drug delivery companies
comparison of Bispecifics and CART, addresses to address scientific and business solutions for the best routes
what makes a good candidate and how to choose of delivery across different therapeutic areas with an emphasis
on emerging technologies and to prepare for the future of R&D
the right patient for each. and clinical care.
MAY 17-18, 2021
Deepu Madduri, MD
Assistant Professor of Medicine -Hematology and Medical
Oncology; Associate Director, Cellular Therapy Service IO COMBINATIONS 360˚
Implementing novel trial designs and addressing business, clinical
and Director of Clinical Operations, Center of Excellence
and scientific developments for combination immunotherapies.
for Multiple Myeloma, The Tisch Cancer Institute and
JUNE, 2021
Icahn School of Medicine, Mount Sinai
MOBILE IN CLINICAL TRIALS
2:55 pm Exploring the value & opportunities of mobile/digital and how
they are challenging clinical trials.
Biomarker Findings from anti- SEPTEMBER 27, 2021
PDL1+anti-VEGF Combination Study in
DPHARM: DISRUPTIVE INNOVATIONS US
Advanced HCC DPharm underscores the promise and challenge of innovation
Biomarker findings from a 200+ patient phase to advance drug development. It features new models and
collaborations to get therapeutics to patients faster. DPharm is
1b study on anti-PDL1+anti-VEGF combination dedicated to challenging creative solutions and finding a way to
in advanced HCC, including tissue multi-omics implement them.
correlates, digital pathology, ctDNA, and single cell SEPTEMBER 28 - 29, 2021
multi-omics analysis will be discussed.
Yulei Wang, PhD PARTNERSHIP OPPORTUNITIES IN DRUG DELIVERY
PODD is a strategic level program with a thorough overview
Principal Scientist, Oncology Biomarker of the latest drug delivery technologies available along with an
Development, Genentech update on deals and opportunities to improve therapies and
extend the life cycle of a drug.
OCTOBER 28-29, 2021
3:10 pm
Conference Concludes CHIEF MEDICAL OFFICER SUMMIT
CMOs from biotechs address the unique challenges associated
with all R&D functions with limited resources, while raising capital
and strategizing for appropriate exits.
OCTOBER 14-15, 2021
23 www.io360summit.comIMMUNO - ONCOLOGY 360° 2021
See the whole slide.
See the whole answer.
Morphology or multiplexing? Brightfield or fluorescence?
Choosing which assay to run on your sample can be a difficult decision. But, with InSituPlex®
technology, you can collect immunofluorescence multiplex data and H&E data on the same
tissue slide — so you don’t have to choose.
Get a comprehensive view into the tumor microenvironment and gather immunological
insights paired with conventional pathology assessments.
InSituPlex gives you the ability to detect multiple markers on single cells, even in the same
cellular compartment, meaning you can accurately interrogate the underlying biology of your
tissue samples and gather more information than ever before. And, you’ll get faster access to
more relevant phenotypes.
So, morphology or multiplexing? How about both.
www.ultivue.com
24 www.io360summit.com
Research Use Only. Not for use in diagnostic procedures.IMMUNO - ONCOLOGY 360° 2021 SPEAKER BIOS
SPEAKER BIOS
Stewart Abbot, PhD Andrea Apolo, MD
Chief Scientific and Operating Officer, Head, Bladder Cancer Section
Adicet Bio National Cancer Institute
Andrea Apolo, MD is a medical oncologist dedicated to improving
Stewart Abbot, PhD, joined Adicet Bio in June 2018 to lead the the lives of patients with genitourinary tumors. She designs and
research of Adicet’s novel immune therapy products. He has over implements clinical trials to test novel agents for the treatment of
20 years of experience in research, early product development urologic cancers. Her research focuses on developing targeted
and translational science initiatives. therapies for bladder cancer and rare genitourinary tumors,
including immunotherapies, angiogenesis inhibitors, and agents
Dr Abbot joined Adicet, from Fate Therapeutics where he served that target MET, and in identifying molecular alterations that will
as Chief Development Officer and oversaw all aspects of late- serve as targets for individualized treatment strategies.
stage research and development of hematopoietic and induced
pluripotent stem cell-based immunotherapeutics. His previous
roles included Executive Director of Integrative Research at
Celgene Cellular Therapeutics (CCT) where he led Integrative Jacob Aptekar, MD, PhD
Research activities that encompassed technology and product Senior Director, Product Management
scouting, alliance identification and business development (Integrated Evidence)
activities, including initiation of engineered T cell programs, Acorn AI, a Medidata company
Senior Director of Research at CCT where his group developed
novel therapeutic candidates based on hematopoietic stem cells Jacob Aptekar, MD, PhD, is Senior Director of Product
and human placenta-derived cells and initiated clinical trials for Management at Acorn AI, a Medidata Solutions company and
placental cells, and head of the General Electric Molecular and part of Dassault Systemes. Dr Aptekar has over 10 years of
Cellular Biology research laboratory at GE’s Global Research experience as a basic science researcher, business leader
Center in Albany, NY. Dr Abbot holds a BSc. in Biological and data scientist. He most recently served as an Associate
Sciences (Edinburgh), MSc in Biomedical Engineering (Glasgow) at McKinsey & Company within their Digital McKinsey practice
and PhD in Pathology (London). — working with public and private sector clients who use
technology to deliver healthcare and develop therapies.
Previously, he founded and led Qurator Inc, a data science
Bruce Adams, PhD company focused on the progression of chronic kidney disease
Staff Scientist and care planning for dialysis. Dr Aptekar received an MD from
10X Genomics the David Geffen School of Medicine at UCLA, his PhD from
UCLA in Neuroscience under the mentorship of Mark Frye, an
Bruce Adams, PhD joined the R&D group at 10x Genomics investigator with the Howard Hughes Medical Institute and an AB
in 2018, and was previously a scientist at Quanticel in Physics from Harvard College.
Pharmaceuticals (acquired by Celgene) where he helped build
primary tumor model platforms for preclinical drug development,
and was a scientist/director at Xcell Biosciences Inc., a life Andrew Baum, MD
science tools company focused on primary cells including solid Head of Global Healthcare; Managing Director,
tumor cancers, stem cells and immune cells. He did his doctoral Equity Research
training in Biology at the University of Victoria (BC, Canada), and Citi
his postdoctoral training at UCSF’s Diabetes Center and the
Institute for Regeneration Medicine. Andrew Baum, MD, joined Citi in September 2011, as the Global
Head of Healthcare Research. He benefits from a deep strategic
insight of the global healthcare value chain, as well as broad
Rafael Amado, MD network of contacts throughout the industry. In 2004, Dr Baum
was one of the earliest commentators to highlight to investors
EVP, Research and Development & CMO the deep structural deficiencies of the historic operating structure
Allogene Therapeutics and the need to evolve towards a radically different model.
Rafael G Amado, MD, is the Executive Vice President of Dr Baum is widely sought after to share his insights with the
Research and Development and Chief Medical Officer of most senior levels of management within the healthcare industry.
Allogene. Dr Amado has over 15 years of biotechnology and He regularly lectures for a number of prestigious organisations
pharmaceutical industry experience leading clinical and research including The Institute of Comparative Law, The World Vaccine
teams. He most recently served as President of R&D, after Congress as well as occasional presentations to some of the
serving as Chief Medical Officer, at Adaptimmune. Previously, leading management consultancies
he held several roles of increasing responsibility at GSK, most
recently as Senior Vice President and Head of Oncology Before joining the firm, Dr Baum was at Morgan Stanley 14-years
R&D. Prior to GSK, Dr Amado served as Executive Director of where he was the top ranked European Pharmaceutical Analyst
Therapeutic Oncology at Amgen, where he was responsible for in the Extel Poll for six years. Dr Baum and his team consistently
worldwide clinical research strategy and execution and oversaw ranked in the top three teams in external EU and Global investor
development activities for several investigational agents for polls (Institutional Investor, Greenwich and Reuters). Before this,
molecularly characterized tumors. Before joining Amgen, he was Dr Baum was a UK pharmaceutical and biotechnology analyst
on the faculty at the University of California, Los Angeles, most at Salomon Brothers. From 1994 to 1996, he was a practicing
recently serving as Assistant Clinical Professor, Department of physician at the Royal National Orthopaedic Radcliffe Hospital
Medicine, Division of Hematology/Oncology. Dr Amado received in Oxford (the medical centre of Oxford University) where he
an MD from the University of Seville School of Medicine and completed his residency. Dr Baum is a member of the American
completed his internship and residency in internal medicine Heart Association, American Society of Oncology and the DIA. He
at Michael Reese Hospital and Medical Center, a University is also a Fellow of the Royal Society of Medicine. Dr Baum holds an
of Chicago-affiliated hospital. He completed a fellowship in MA in Physiological Sciences and an MD from Oxford University.
hematology/oncology at the University of California, Los Angeles.
25 www.io360summit.comYou can also read
